No difference in the rate of change in telomere length or telomerase activity in HIV-Infected patients after three years of darunavir/Ritonavir with and without nucleoside analogues in the monet trial

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Solomon, Ajantha ^a   Tennakoon, Surekha ^a   Leeansyah, Edwin ^b   Arribas, Jose ^c   Hill, Andrew ^d   Van Delft, Yvon ^e   Moecklinghoff, Christiane ^f   Lewin, Sharon R ^a  

^a MONASH UNIVERSITY   (Australia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Janssen   (United Kingdom)

^e Janssen   (Netherlands)

^f Janssen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; NUCLEOSIDE; RITONAVIR; SULFONAMIDE; TELOMERASE;

ADULT; AGE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE; TELOMERE LENGTH; TELOMERE SHORTENING; TREATMENT DURATION; CHEMISTRY; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NUCLEOSIDES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TELOMERASE; TELOMERE;

EID: 84934300210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109718     Document Type: Article

References (17)

1. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, et al. (2013) HIv infection and the risk of acute myocardial infarction. JAMA Internal Medicine 173: 614-622.
2. Justice AC, Braithwaite RS (2012) Lessons learned from the first wave of aging with HIV. AIDS 26 Suppl1: S11-18.
3. Barrett EL, Richardson DS (2011) Sex differences in telomeres and lifespan. Aging Cell 10: 913-921.
4. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, et al. (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: A nested case-control study. Lancet 369: 107-114.
5. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA (2003) Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361: 393-395.
6. Heidinger BJ, Blount JD, Boner W, Griffiths K, Metcalfe NB, et al. (2012) Telomere length in early life predicts lifespan. Proc Natl Acad Sci U S A 109: 1743-1748.
7. Palmer LD, Weng N, Levine BL, June CH, Lane HC, et al. (1997) Telomere length, telomerase activity, and replicative potential in HIV infection: Analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med 185: 1381-1386.
8. Rickabaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, et al. (2011) The dual impact of HIV-1 infection and aging on naive CD4 T-cells: Additive and distinct patterns of impairment. PLoS One 6: e16459.
9. Pathai S, Lawn SD, Gilbert CE, McGuinness D, McGlynn L, et al. (2013) Accelerated biological aging in HIV-infected individuals in South Africa: A casecontrol study. AIDS.
10. Franzese O, Adamo R, Pollicita M, Comandini A, Laudisi A, et al. (2007) Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J Med Virol 79: 639-646.
11. Liu X, Liu J, Ogawara T, Kurashina Y, Yashi R, et al. (2007) Influence of nucleoside analogue treatment on telomere length and TRF2 amount in human HL60 cells. Nucleic Acids Symp Ser (Oxf): 253-254.
12. Wolthers KC, Otto SA, Wisman GB, Fleury S, Reiss P, et al. (1999) Normal Tcell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood 93: 1011-1019.
13. Hukezalie KR, Thumati NR, Cote HC, Wong JM (2012) In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS One 7: e47505.
14. Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, et al. (2013) Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: A potential factor contributing to HIV-associated accelerated aging. J Infect Dis 207: 1157-1165.
15. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, et al. (2012) The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load, 50 HIV-1 RNA copies/mL at baseline. HIV Med 13: 398-405.
16. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, et al. (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111: 2307-2312.
17. Altman DG, Bland JM (1995) Absence of evidence is not evidence of absence. BMJ 311: 485.